Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

3 Months Ended

Mar. 31, 2020

Payables and Accruals [Abstract]

Accrued Expenses

8.	ACCRUED EXPENSES

Accrued expenses consisted of the following:

		March 31, 2020				December 31, 2019
Accrued clinical operations and trials costs		$	16,145,019			$	14,242,669
Accrued product development costs			3,232,262				3,573,231
Accrued compensation			2,849,954				3,673,111
Accrued other			1,289,119				958,928
Total		$	23,516,354			$	22,447,939